How much do you know about Decapeptyl SR 11

Summary of Decapeptyl SR 11.25mg (Triptorelin Pamoate) Medication Information

• Decapeptyl SR 11.25mg is a prescription-only medicine used to treat locally advanced, non-metastatic prostate cancer, metastatic prostate cancer, endometriosis, and central precocious puberty.
• The active ingredient in this medication is triptorelin pamoate, with a dosage of 15mg in each vial, containing an overage to ensure that a dose of 11.25mg is administered to the patient.
• Decapeptyl SR 11.25mg is administered through intramuscular injection every three months for prostate cancer and central precocious puberty, while endometriosis treatment requires an injection every three months, initiated within the first five days of the menstrual cycle, for a maximum of six months.
• The dosage does not require adjustment in elderly patients with prostate cancer.
• Decapeptyl SR 11.25mg is also available as a 1-month treatment (Decapeptyl SR 3mg) and a 6-month treatment (Decapeptyl SR 22.5mg) for prostate cancer and a 1-month treatment for endometriosis.
• GnRH analogues used to treat metastatic prostate cancer should be continued upon the development of castrate-resistant prostate cancer, as per relevant guidelines.
• The use of Decapeptyl SR 11.25mg is contraindicated in patients with hypersensitivity to GnRH, its analogues, or any of the excipients listed in section 6.1, and in pregnant or lactating women.
• The use of GnRH agonists may cause a reduction in bone mineral density, with preliminary data suggesting that bisphosphonates may reduce bone mineral loss in men.
• Treatment of central precocious puberty with Decapeptyl SR 11.25mg should be under the supervision of a paediatric endocrinologist or paediatrician/endocrinologist with expertise in the treatment of central precocious puberty, and treatment should be stopped around the physiological age of puberty in boys and girls.
• In endometriosis patients treated with GnRH analogues, the addition of add-back therapy (ABT) may reduce bone mineral density loss and vasomotor symptoms, and ABT should be co-administered with GnRH analogues if appropriate, taking into account the risks and benefits of each treatment.
• The maximum duration of treatment for endometriosis with Decapeptyl SR 11.25mg should not exceed six months (two injections) due to concerns about bone density losses.
• Treatment of locally advanced, non-metastatic prostate cancer with Decapeptyl SR 11.25mg is an alternative to surgical castration. It can also be used as adjuvant treatment to radiotherapy or radical prostatectomy in patients with high-risk local

Test your knowledge on the medication Decapeptyl SR 11.25mg (Triptorelin Pamoate) with this informative quiz. Learn about the uses, dosage, administration, contraindications, and potential side effects of this prescription-only medicine. Challenge yourself with questions on the treatment of prostate cancer, endometriosis, and central precocious puberty. Take the quiz now and improve your understanding of this medication.